| Caitlin M Durfey, | |
|
590 Fishers Station Dr, Suite 130, Victor, NY 14564-9744 | |
| (585) 924-7207 | |
| (585) 924-7049 |
| Full Name | Caitlin M Durfey |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 590 Fishers Station Dr, Victor, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184974248 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 022240 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Caitlin M Durfey, 590 Fishers Station Dr, Suite 130, Victor, NY 14564-9744 Ph: (585) 924-7207 | Caitlin M Durfey, 590 Fishers Station Dr, Suite 130, Victor, NY 14564-9744 Ph: (585) 924-7207 |
News Archive
More patients could be diagnosed earlier with non-alcoholic fatty liver disease after a cohort study presented at the International Liver Congress 2013 identified variants within four genes significantly associated with the histological features of the disease.
Pathologic changes of the retina caused by diabetes is the leading cause of blindness in working adults. Diabetic retinopathy has no known cure, treatment options are inadequate, and prevention strategies offer limited protection. In the first of its kind, a report in The American Journal of Pathology describes a potential new intraocular treatment based on manipulating the renin angiotensin system (RAS) that both prevents and reverses some characteristics of diabetic retinopathy in a mouse model.
A new survey cautions physicians that drugs commonly prescribed for patients suffering from immunological disorders such as rheumatoid arthritis and inflammatory bowel disease may carry risks of serious infections other than the known risk of tuberculosis. The survey published is in the June 1 issue of Clinical Infectious Diseases, currently available online.
Today at the Society of Gynecologic Oncology (SGO) 43rd Annual Meeting on Women's Cancer®, Dr. Jonathan Ledermann, Director of Cancer Services and Professor of Medical Oncology at University College London, presented new data updating the overall survival of women enrolled in a "Phase II randomized placebo-controlled study of olaparib (AZD2281) maintenance in patients with platinum-sensitive relapsed serous ovarian cancer."
› Verified 9 days ago
Catherine C Higby, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 590 Fishers Station Dr Ste 130, Victor, NY 14564 Phone: 585-924-7207 Fax: 585-924-7049 | |
Kathleen D Lopez, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 590 Fishers Station Dr, Suite 130, Victor, NY 14564 Phone: 585-924-7207 Fax: 585-924-7049 | |
Christine Lobene, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 590 Fishers Station Dr, Suite 130, Victor, NY 14564 Phone: 585-924-7207 Fax: 585-924-7049 | |
Elise Tiffany Maus, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 590 Fishers Station Dr Ste 130, Victor, NY 14564 Phone: 585-924-7207 | |
Jenna Marie Davies, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 590 Fishers Station Dr, Suite 130, Victor, NY 14564 Phone: 585-924-7207 | |
Mrs. Sarah Sirianni, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 590 Fishers Station Dr Ste 130, Victor, NY 14564 Phone: 585-924-7207 | |
Natalie Adiletta, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 590 Fishers Station Dr Ste 130, Victor, NY 14564 Phone: 585-924-7207 |